Previous research has shown that EGFR mutations and KRAS mutations rarely occur together, and the use of EGFR-targeted drugs alone to treat KRAS-mutant lung adenocarcinoma has not shown significant clinical benefits. Here, KRAS is linked to lung adenocarcinoma.